of preclinical and clinical non-oncology programs supported by
A mix of
innovative molecules,
new indications, and biosimilars

A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.

Download Pipeline Chart

*   Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

   In addition to the above programs, AMJEVITA/AMGEVITA, MVASI, and KANJINTI have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). We are also pursuing other biosimilar product candidates in earlier-stage clinical development.